Chemotherapy-Induced Nausea and Vomiting (CINV) Market Overview:

The Global Chemotherapy-Induced Nausea And Vomiting (CINV) Market was valued at $1,663 million in 2015, and is estimated to reach $2,659 million by 2022, registering a CAGR of 7.1% during the forecast period 2016-2022.

Nausea and vomiting (emesis) caused by cancer drugs is referred to as chemotherapy-induced nausea and vomiting (CINV). Patient may experience nausea and vomiting within 24 hours (acute) or after 24 hours (delayed) of chemotherapy. Chemotherapy-induced nausea and vomiting leads to the deferment or refusal of therapeutic chemotherapy treatment for cancer. The report analyzes chemotherapy-induced nausea and vomiting (CINV) drugs market based on disease, class, and region.

Get more information on this report : Request Sample Pages

Segment Review

The global CINV market encompasses patient pool type and geography of the CINV drugs market. The patient pool type segment includes Aloxi (palonosetron), Kytril Generic (Granisetron), Emend (aprepitant), Netupitant-Palonosetron FDC, and others. Netupitant-palonosetron is the fastest growing therapy or drug type for this market owing to increasing adoption to CINV drugs with rising cancer patients going for chemotherapy treatment.

The key impacting factors include growth in number of patients undergoing chemotherapy and the rising compliance to CNIV drugs due to increase in adoption of novel drug delivery methods such as combination therapies & transdermal patches. Further, the market is also influenced by technology developments to discover new high potential drugs, thus creating opportunity for the market growth. However, high price of CINV drugs restrict the growth.

Presently, patient pool segment witnesses a high rate of CINV drugs adoption due to increasing number of patients with side effects associated with chemotherapeutic drug use. Further, the development and launch of novel drug delivery methods for CINV drugs is expected to boost patient compliance rates and the demand for CINV drugs. In addition, improvement in the control of CINV has occurred with the use of aprepitant, the first agent available in the drug class of neurokinin-1 (NK-1). One of the potential factors that explain this suboptimal response is variability in genes encoding enzymes and proteins, which play a role in metabolism, transport, and receptors related to antiemetic drugs.

Get more information on this report : Request Sample Pages

Based on geography, the market is segmented into North America, Europe, Asia-Pacific, and LAMEA. Asia-Pacific is the fastest growing market at a CAGR of 9.8% owing to the increase in the cancer population and use of chemotherapeutic drugs. Aloxi and Zofran are the key CINV drugs with the largest share and boosting the growth of CINV market in Asia-Pacific during the forecast period 2016-2022. Other driving factors of CINV market in Asia-Pacific are increase in the healthcare spending and health infrastructure.  

The key players in the global chemotherapy-induced nausea and vomiting (CINV) drugs are GlaxoSmithKline plc, Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co., Inc., and Tesaro, Inc

KEY BENEFITS

• The study provides in-depth analyses of the CINV market along with the current trends and future estimations to elucidate the imminent investment pockets.
• The report explores the dynamics of the market influencing the adoption and growth of the CINV drugs market
• The report provides a quantitative analysis for the period of 2014-2022 to enable stakeholders to capitalize on the prevailing opportunities in the industry.
• Extensive analysis of the global market helps understand CINV drugs developed and marketed by the key companies.
• Competitive intelligence of market players highlights the business practices and trends across various regions.

CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) KEY MARKET SEGMENTS

The global CINV market is segmented based on product type and geography.

By Patient Pool Type

• Aloxi, Kytril
• Emend
• Netupitant-Palonosetron
• Others

By Geography

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • Rest of Asia-Pacific
• LAMEA
  • Latin America
  • Middle East
  • Africa

 Key Market Segments

• By PATIENT POOL
  • Netupitant-Palonosetron FDC
  • Aloxi (palonosetron)
  • Kytril Generic (Granisetron)
  • Emend (aprepitant)
• By GEOGRAPHY
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
    • Malaysia
    • Indonesia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • UAE
    • Argentina
    • Rest of LAMEA

 
Key Market Players

• Tesaro, Inc.
• GlaxoSmithKline plc
• Amneal Pharmaceuticals
• Merck & Co., Inc
• Acacia Pharma
• Cadila Pharmaceuticals Limited
• Kyowa Kirin, Inc.
• Heron Therapeutics, Inc.
• Insys Therapeutics, Inc
• Helsinn Holding S.A.

CHAPTER 1 INTRODUCTION

1.1 Report Description
1.2 Key Benefits
1.3 Key Market Segments
1.4 Research Methodology

1.4.1 Secondary Research
1.4.2 Primary Research
1.4.3 Analyst Tools and Models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 CXO Perspective

CHAPTER 3 MARKET OVERVIEW

3.1 Market Definition and Scope
3.2 Key Findings

3.2.1 Top Impacting Factors
3.2.2 Top Investment Pockets

3.3 Porters Five Force Analysis
3.4 Drivers

3.4.1 Growing Number of patients undergoing Chemotherapy
3.4.2 Growing research and development efforts in order to discover a universal antiemetic therapy
3.4.3 Introduction of novel delivery methods to improve patient compliance.
3.4.4 Advancements in technology to discover new potential drug targets

3.5 Restrains

3.5.1 Increasing side effects of CINV drugs
3.5.2 High cost associated with the new drug discovery and in developing regions.

3.6 Opportunities

3.6.1 Efficacy of combination therapy is expected to improve.
3.6.2 Improved quality of life for patients with cancer.

3.7 Market Trends

CHAPTER 4 CINV MARKET BY PATIENT POOL

4.1 Overview
4.2 Netupitant-Palonosetron FDC

4.2.1 Key market trends
4.2.2 Key growth factors & opportunities
4.2.3 Market size & forecasts

4.3 Aloxi (palonosetron)

4.3.1 Key market trends
4.3.2 Key growth factors & opportunities
4.3.3 Market size & forecasts

4.4 Kytril Generic (Granisetron)

4.4.1 Key market trends
4.4.2 Key growth factors & opportunities
4.4.3 Market size & forecasts

4.5 Emend (aprepitant)

4.5.1 Key market trends
4.5.2 Key growth factors & opportunities
4.5.3 Market size & forecasts

CHAPTER 5 CINV MARKET BY GEOGRAPHY

5.1 North America

5.1.1 Key Market Trends
5.1.2 Key Growth Factors and Opportunities
5.1.3 Market Size and Forecast

5.2 Europe

5.2.1 Key Market Trends
5.2.2 Key Growth Factors and Opportunities
5.2.3 Market Size and Forecast

5.3 Asia-Pacific

5.3.1 Key Market Trends
5.3.2 Key Growth Factors and Opportunities
5.3.3 Market Size and Forecast

5.4 Latin America, Middle East and Africa (LAMEA)

5.4.1 Key Market Trends
5.4.2 Key Growth Factors and Opportunities
5.4.3 Market Size and Forecast

CHAPTER6 COMPANY PROFILES

6.1 Helsinn Holding S.A.

6.1.1 Company Overview
6.1.2 Key Strategies and Developments
6.1.3 SWOT Analysis

6.2 Heron Therapeutics, Inc.

6.2.1 Company Overview
6.2.2 Business Performance
6.2.3 Key Strategies and Developments
6.2.4 SWOT Analysis

6.3 Merck & Co., Inc

6.3.1 Company Overview
6.3.2 Business Performance
6.3.3 Key Strategies and Developments
6.3.4 SWOT Analysis

6.4 GlaxoSmithKline plc

6.4.1 Company Overview
6.4.2 Business Performance
6.4.3 Key Strategies and Developments
6.4.4 Key Strategies and Developments
6.4.5 SWOT Analysis

6.5 Cadila Pharmaceuticals Limited

6.5.1 Company Overview
6.5.2 Business Performance
6.5.3 Key Strategies and Developments
6.5.4 Key Strategies and Developments
6.5.5 SWOT Analysis

6.6 Amneal Pharmaceuticals

6.6.1 Company Overview
6.6.2 Business Performance
6.6.3 Key Strategies and Developments
6.6.4 Key Strategies and Developments
6.6.5 SWOT Analysis

6.7 Kyowa Kirin, Inc.

6.7.1 Company Overview
6.7.2 Business Performance
6.7.3 Key Strategies and Developments
6.7.4 Key Strategies and Developments
6.7.5 SWOT Analysis

6.8 Acacia Pharma

6.8.1 Company Overview
6.8.2 Business Performance
6.8.3 Key Strategies and Developments
6.8.4 Key Strategies and Developments
6.8.5 SWOT Analysis

6.9 Insys Therapeutics, Inc

6.9.1 Company Overview
6.9.2 Business Performance
6.9.3 Key Strategies and Developments
6.9.4 Key Strategies and Developments
6.9.5 SWOT Analysis

6.10 Tesaro, Inc.

6.10.1 Company Overview
6.10.2 Business Performance
6.10.3 Key Strategies and Developments
6.10.4 Key Strategies and Developments
6.10.5 SWOT Analysis

*Details on financial performance, strategic moves and developments and SWOT analysis may not be captured for unlisted companies.

List of Figures

FIG. 1 TOP IMPACTING FACTORS
FIG. 2 TOP INVESTMENT POCKETS
FIG. 3 PORTERS FIVE FORCES ANALYSIS OF LITHIUM-ION BATTERY MARKET
FIG. 4 WORLD CINV MARKET BY TYPE, 2015(PIE CHART OF GLOBAL NUMBERS BY TYPE)
FIG. 5 WORLD CINV MARKET BY GEOGRAPHY, 2015(PIE CHART OF GLOBAL NUMBERS BY GEOGRAPHY)
FIG. 6 NET SALES OF HERON THERAPEUTICS, INC., 2013-2015 ($MILLION)
FIG. 7 NET SALES OF HERON THERAPEUTICS, INC., BY SEGMENT (%), 2015
FIG. 8 NET SALES OF HERON THERAPEUTICS, INC., BY GEOGRAPHY (%), 2015
FIG. 10 NET SALES OF MERCK & CO., INC, 2013-2015 ($MILLION)
FIG. 11 NET SALES OF MERCK & CO., INC., BY GEOGRAPHY (%), 2015
FIG. 11 NET SALES OF MERCK & CO., INC., BY SEGMENT (%), 2015
FIG. 12 NET SALES OF GLAXOSMITHKLINE PLC ., 2013-2015 ($MILLION)
FIG. 13 NET SALES OF GLAXOSMITHKLINE PLC, BY SEGMENT (%), 2015
FIG. 14 NET SALES OF GLAXOSMITHKLINE PLC, BY GEOGRAPHY (%), 2015
FIG. 18 NET SALES OF KYOWA KIRIN, INC., 2013-2015 ($MILLION)
FIG. 13 NET SALES OF KYOWA KIRIN, INC., BY SEGMENT (%), 2015
FIG. 14 NET SALES OF KYOWA KIRIN, INC., BY GEOGRAPHY (%), 2015
FIG. 22 REVENUE OF INSYS THERAPEUTICS, INC., 2013-2015 ($MILLION)
FIG. 13 NET SALES OF INSYS THERAPEUTICS, INC., BY SEGMENT (%), 2015
FIG. 14 NET SALES OF INSYS THERAPEUTICS, INC., BY GEOGRAPHY (%), 2015
FIG. 22 REVENUE OF TESARO, INC, 2013-2015 ($MILLION)
FIG. 13 NET SALES OF TESARO, INC, BY SEGMENT (%), 2015
FIG. 14 NET SALES OF TESARO, INC, BY GEOGRAPHY (%), 2015

List of Tables

TABLE 1 WORLD CINV MARKET BY PATIENT POOL(NETUPITANT-PALONOSETRON FDC) MARKET, ($MILLION), GROWTH (%)2014-2022
TABLE 2 WORLD CINV MARKET BY PATIENT POOL( ALOXI) , ($MILLION), GROWTH (%)2014-2022
TABLE 3 WORLD CINV MARKET BY PATIENT POOL(KYTRIL GENERIC ) , ($MILLION), GROWTH (%)2014-2022
TABLE 4 WORLD CINV MARKET BY PATIENT POOL(EMEND ) , ($MILLION), GROWTH (%)2014-2022
TABLE 5 NORTH AMERICA CINV MARKET, ($MILLION), GROWTH (%)2014-2022
TABLE 6 EUROPE CINV MARKET, ($MILLION), GROWTH (%)2014-2022
TABLE 7 ASIA CINV MARKET, ($MILLION), GROWTH (%)2014-2022
TABLE 8 LAMEA CINV MARKET, ($MILLION), GROWTH (%)2014-2022
TABLE 9 HELSINN HOLDING S.A.COMPANY SNAPSHOT
TABLE 9 HELSINN HOLDING S.A.OPERATING SEGMENTS
TABLE 10 HERON THERAPEUTICS, INC. COMPANY SNAPSHOT
TABLE 11 HERON THERAPEUTICS, INC.OPERATING SEGMENTS
TABLE 12 MERCK & CO., INC. COMPANY SNAPSHOT
TABLE 13 MERCK & CO., INC.OPERATING SEGMENTS
TABLE 14 GLAXOSMITHKLINE PLC COMPANY SNAPSHOT
TABLE 15 GLAXOSMITHKLINE PLC OPERATING SEGMENTS
TABLE 16 CADILA PHARMACEUTICALS LIMITED COMPANY SNAPSHOT
TABLE 17 CADILA PHARMACEUTICALS LIMITED OPERATING SEGMENTS
TABLE 18 AMNEAL PHARMACEUTICALS COMPANY SNAPSHOT
TABLE 19 AMNEAL PHARMACEUTICALS OPERATING SEGMENTS
TABLE 20 KYOWA KIRIN, INC. COMPANY SNAPSHOT
TABLE 21 KYOWA KIRIN, INC. OPERATING SEGMENTS
TABLE 22 ACACIA PHARMA COMPANY SNAPSHOT
TABLE 23 ACACIA PHARMA OPERATING SEGMENTS
TABLE 24 INSYS THERAPEUTICS, INC. COMPANY SNAPSHOT
TABLE 25 INSYS THERAPEUTICS, INC. OPERATING SEGMENTS
TABLE 26 TESARO, INC. COMPANY SNAPSHOT
TABLE 27 TESARO, INC. OPERATING SEGMENTS